Background: Increasingly more nonbinary patients are obtaining better access for gender-affirming chest surgery (top surgery), representing an important subset of patients who undergo such surgery. Objective: We review our experience at gender-affirming chest surgery in nonbinary versus transmasculine patients in an integrated health care setting. Methods: We performed a retrospective study of nonbinary and transmasculine patients who underwent gender-affirming chest surgery from May 1, 2012, to December 27, 2017. Results: There were 111 nonbinary patients and 665 transmasculine patients included in the final analyses. Nonbinary patients were more likely to seek more than 1 surgical consultations than transmasculine patients (24.3% vs 1.7%, respectively, P < 0.0001). More nonbinary patients (17.3%) indicated nipple sensation to be important relative to their transmasculine counterparts (0.4%, P < 0.0001). Fewer nonbinary patients were on testosterone before surgery (33.64%) in comparison to transmasculine patients (86.14%, P < 0.0001). When only prior reduction mammaplasty or top surgery were considered, nonbinary patients (8.1%) were more likely than transmasculine patients (3.5%) to have had a prior chest surgery. When evaluating patients who did not have prior chest surgery before undergoing top surgery at our institution (n = 721), rates of major complications, minor complications, as well as revisions, were comparable between nonbinary and transmasculine patients. Conclusions: This study demonstrated that more nonbinary patients requested nonflat chests relative to their transmasculine counterparts. Both groups in our sample displayed comparable rates of complications after top surgery.
1 November 2021 in Journal of Plastic, Reconstructive & Aesthetic Surgery
Background/Objectives: Acellular dermal matrix (ADM) is commonly used for breast reconstruction with the proposed benefit of stabilizing the implant pocket and enhancing breast shape. However, some reports highlight safety concerns regarding ADM use. This study evaluates short and long-term unplanned return to the operating room (OR) for immediate implant-based reconstruction with or without ADM. Methods: Females who underwent primary mastectomy with direct to implant reconstruction for breast cancer or risk reduction (2010–2020) were identified using an integrated healthcare system’s EHR. Multivariable Poisson regression was conducted to evaluate return to OR outcomes at early (<1 year), intermediate (1–2 years), and long term (≥2 years) periods for ADM versus without. Results: The cohort included 2886 patients, 69.8% with ADM. Overall, no differences were observed for OR returns for ADM compared to none. For unilateral procedures, a lower rate of return to OR was observed at 0–1 year (IRR = 0.74, 95% CI = 0.58–0.95) and >2 years (IRR = 0.52, 95% CI = 0.29–0.94). Conclusions: The lack of overall difference suggests ADM usage did not impact risk of complications nor improve surgical outcomes. For unilateral cases, ADM is associated with lower rates of return to OR at a higher cost to the healthcare system. Surgeons may use their discretion whether ADM is appropriate for breast reconstruction.
Background: Few studies have compared the risk of reoperation by timing in breast reconstruction surgery after mastectomy. We evaluated the first and total number of reoperations by reconstruction timing in women with breast cancer undergoing primary mastectomy. Methods: A cohort study of 23,301 primary mastectomies in women with breast cancer undergoing either immediate breast reconstruction (IBR) or delayed reconstruction was carried out within Kaiser Permanente between 2010 and 2022. The first reoperation rate was calculated using cause-specific Cox Proportional Hazards Models, while Multiplicative Cox Proportional Hazards Models were used to account for mortality and timing in reoperation. Patients were continuously monitored for death, outcome of interest, loss to follow-up through healthcare membership termination, or study end date (31 December 2022). Results: In total, 78.4% (n = 18,276) of the cohort underwent IBR. The average follow-up time was 5.9 years (±3.8). The following covariates were imbalanced (standardized mean difference [SMD] ≥ 0.20) between IBR and delayed groups: BMI, smoking status, year of mastectomy, bilateral procedures, and reconstruction type. The crude incidence of first reoperation was 33.04% vs. 31.72% in IBR vs. delayed patients and the risk of reoperation was 18% higher in IBR patients (HR = 1.18, 95% CI = 1.12–1.25). There was no difference in the risk of reoperation by timing (p > 0.05) when assessing multiple reoperations. The reoperation risk was the highest for IBR patients who did not complete reconstruction or single-stage reconstruction. In addition, the first reoperation rate of IBR patients was higher in those who underwent expander–implant-based reconstruction. Conclusions: The first reoperation rate was higher in IBR patients compared to those who delayed reconstruction, although we failed to detect a difference for multiple returns to surgery, except in certain subgroups. Assessing reoperation risk by timing among different reconstruction modalities can aid patients in making informed decisions about the type of breast reconstruction to undergo.